RESEARCH, WITH CONTEXT
Big numbers.
Read the small print.
We don’t yet have an evidence-based revenue forecast for Afterglow. The numbers on the cards belong to reference businesses or a supplier’s client brands.
The default order puts available USD revenue signals highest first, followed by the research’s launch priority. Annual sales, annualized run rates, brand milestones and aggregate sales are different metrics; each keeps its own label and period. This is a browsing aid, not a ranking of likely profitability.
“Not disclosed” means we have no suitable category revenue benchmark. It does not mean zero demand. Unit counts, product prices, growth percentages and EUR portfolio totals appear only in the relevant details.
Open a product to see the evidence, source links and limitations. Switch to Launch priority for the original research order, which also considers effort, inventory and sourcing constraints.
144 leads ≠ 144 ready-to-launch suppliers. The directory includes white-label services, manufacturers, resale brands, affiliate programmes and discovery platforms. Exact SKUs, branding rights, fulfilment and commercial terms need confirmation. The concept packaging is not a supplier-approved design.
The research’s 32 categories become 31 visual lines here: research/injectable peptides are outside this supplement MVP. Scratch-and-sniff cards are a marketing idea, rather than an item to sell.
Research snapshot: 1 October 2026. No checkout, payment or order collection is enabled.
a little